| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:BEAM), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.2, a high estimate of $57.00, and a low estimate of $35.00. This current average reflects an increase of 52.32% from the previous average price target of $30.33.
The standing of Beam Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Nierengarten | Wedbush | Maintains | Outperform | $57.00 | - |
| Kostas Biliouris | BMO Capital | Maintains | Outperform | $57.00 | - |
| Gena Wang | Barclays | Raises | Equal-Weight | $42.00 | $26.00 |
| Luca Issi | RBC Capital | Raises | Sector Perform | $35.00 | $27.00 |
| Eric Joseph | JP Morgan | Raises | Overweight | $40.00 | $38.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Beam Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Beam Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Beam Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 1478.04%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Beam Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 45.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Beam Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.38% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BEAM
